---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-020517"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:24:06.162874+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Context Therapeutics releases updated corporate presentation focused on T cell engagers for solid tumors

## Summary
- Presentation updated March 23, 2026 for investor and analyst meetings.
- Slides emphasize advancing T cell engager platform for solid tumors; no financial or clinical data disclosed.
- Slides 15 and 32 incorporated into Item 8.01, but specific content not detailed in filing.
- Previous presentation replaced; no new pipeline milestones, partnerships, or financing announced.

## SEC filing metadata
- accession: 0001628280-26-020517
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/0001628280-26-020517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/cntx-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-020517
- JSON: https://secwatch.observer/filing/0001628280-26-020517.json
- Plain text: https://secwatch.observer/filing/0001628280-26-020517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.